Chronic hepatitis B is not only a threat to the health of the general public, but also a great drain on social and medical resources. Although it is difficult to completely eliminate the hepatitis B virus with current treatment, it is possible to achieve good results with proper treatment, thus preventing chronic hepatitis B from developing into liver cirrhosis or liver cancer. As the majority of hepatitis B patients do not know much about the basic knowledge and treatment status of chronic hepatitis B, but they are eager to seek medical treatment. In a large number of exaggerated medicine and medical advertising misleading, the phenomenon of indiscriminate medical care and medication is very serious. This has led to many patients being deceived and even delayed in treatment, leading to aggravation of the disease. So, how should chronic hepatitis B patients actually cope with it? The following points are available for patients’ reference. 1, not all hepatitis B virus infection is suitable for antiviral treatment, like hepatitis B virus carriers do not necessarily need antiviral treatment. The so-called hepatitis B virus carriers are: 6 months after infection with hepatitis B virus still failed to clear the hepatitis B virus, regardless of major or minor triplets, DNA positive or negative, as long as liver function continues to be normal, no obvious symptoms, can be considered as hepatitis B virus carriers. The situation is better for those who have small hepatitis B, negative DNA, normal liver function and no obvious symptoms. These hepatitis B virus carriers generally do not need special treatment and can work, study and live like normal people. However, hepatitis B virus carriers should have regular medical checkups and closely observe changes in their condition in order to detect early changes in their condition and provide timely treatment. 2.Which hepatitis B virus infected people need antiviral treatment? Anyone with abnormal liver function (usually refers to glutamate transaminase i.e. ALT is higher than normal, normal ALT is <40IU/ml) and positive HBVDNA, regardless of major or minor triplets, should be treated with antiviral therapy as long as economic conditions allow. Or although the ALT is not very high, but after liver histological examination found that the liver has obvious inflammation, should also be antiviral treatment. 3, the current antiviral drugs with better efficacy mainly include: interferon class, there are ordinary interferon and long-acting interferon; and nucleoside analogues, there are lamivudine, adefovir, entecavir, tipifudine, tenofovir. Although these drugs have definite efficacy, they also have limitations and can only be used under the guidance of a specialist in a regular hospital to obtain the best efficacy and avoid adverse effects. This is because while it is important that the antiviral effect of the drug itself is strong, its efficacy is also related to the patient's own immune status and the virus itself. In addition to these drugs, there are a few immunomodulatory drugs that have a complementary effect on hepatitis B antiviral therapy. Other therapies that supposedly turn hepatitis B negative, or so-called gene therapy for hepatitis B, are not credible. Practice shows that with the existing antiviral drugs, the goal of inhibiting hepatitis B virus replication, blocking the progression of liver inflammatory lesions, maintaining long-term stability of liver function, and reducing or preventing the occurrence of liver fibrosis or cirrhosis, or even liver cancer, can be achieved. As for patients who are already suffering from cirrhosis or cirrhotic ascites, they should adhere to long-term antiviral and anti-cirrhotic treatment therapy and not stop the medication. As long as long-term treatment is adhered to, there are already many cirrhotic patients whose cirrhosis has been reduced or even disappeared. Of course, it is never easy to completely remove the hepatitis B virus from the patient's body. However, under the existing antiviral drug therapy, if the doctor uses the right medicine, especially after long-term treatment with long-acting interferon therapy or nucleoside analogues, many of the patients treated by the author have already achieved the ideal effect of hepatitis B surface antigen transfer negative, hepatitis B DNA transfer negative, liver function normal, that is, the patient's hepatitis B has been clinically cured. The claim that one or several courses of treatment can make hepatitis B completely negative is completely misleading to hepatitis B patients.